Clinical efficiency of intra-cavity biotherapy patients with malignant effusions


Cite item

Full Text

Abstract

The study evaluatedfeasibility, safety and effectiveness of cell biotherapy based on allogenic LAK-cells in combination with recombinant interleukin-2 (IL-2) used for sistem antitumor immunotherapy. The clinical study involved cancer patients with metastatic effusions resistant to systemic chemotherapy. The results showed that intra-cavity immunotherapy was highly effective and well tolerated in treatment of patients with malignant effusions.

About the authors

Konstantin S. Titov

N.N. blokhin Russian Cancer Research Center; N.I. Pirogov Russian National Research Medical University

Email: ks-titov@mail.ru
MD, PhD 115478, Moscow, Russian Federation

L. V Demidov

N.N. blokhin Russian Cancer Research Center

115478, Moscow, Russian Federation

I. Zh Shubina

N.N. blokhin Russian Cancer Research Center

115478, Moscow, Russian Federation

A. N Gritsay

N.N. blokhin Russian Cancer Research Center

115478, Moscow, Russian Federation

A. V Egorova

N.I. Pirogov Russian National Research Medical University

117997,Moscow, Russian Federation

M. V Kiselevsky

N.N. blokhin Russian Cancer Research Center

115478, Moscow, Russian Federation

References

  1. Киселевский М.В. Адоптивная иммунотерапия при злокачественных опухолях. Вестник РАМН. 2003;1: 40-4.
  2. Сельчук В.Ю., Бычков М.Б., Киселевский М.В. ред. Опухолевые серозиты. М.: Практическая медицина; 2011.
  3. Титов К.С., Демидов Л.В, Шубина И.Ж., Киселевский М.В. Сравнение эффективности и переносимости внутрибрюшинной клеточной и ИЛ-2-иммунотерапии у больных с химиорезистентными асцитными формами рака желудка. Российский онкологический журнал. 2014; 3: 24-8.
  4. Hontscha C., Borck Y., Zhou H., Messmer D., Schmidt-Wolf I.G.H. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J. Cancer Res. Clin. Oncol. 2011; 137 (2): 305-10.
  5. Manjili M.H. Revisiting cancer immunoediting by understanding cancer immune complexity. J. Pathol. 2011; 224 (1): 5-9.
  6. Sutlu T., Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J. Intern. Med. 2009; 266(2): 154-81.
  7. Wang E., Panelli M.C., Monsurro V., Marincola F.M. A global approach to tumor immunology. Cell Mol. Immunol. 2004; 1 (4): 256-65.
  8. Xue S.A., Stauss H.J. Enhancing immune responses for cancer therapy. Cell Mol. Immunol. 2007; 4 (3): 173-84.
  9. June C.H. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 2007; 117 (6): 1466-76.
  10. Rosenberg S.A., Lotze M.T., Yang J.C., Topalian S.L., Chang A.E., Schwartzentruber D.J. et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 1993; 85 (8): 622-32.
  11. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J. Cancer. 2011; 2: 363-8.
  12. Liu X., Li D., Zhang C. et al. Treatment of 121 patients with malignant effusion due to advanced lung cancer by intrapleural transfer of autologous or allogeneic LAK cells combined with rIL-2. Chin. Med. Sci. J. 1993; 8 (3): 186-9.
  13. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295: 2097-100.

Copyright (c) 2015 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies